Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
STAT22h
The view from overseas on tumult in U.S. science
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...
Corbus Pharmaceuticals falls after trial data for lead asset
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of its ...
FierceBiotech23h
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...